Naringenin inhibits extracellular matrix production via extracellular signal-regulated kinase pathways in nasal polyp-derived fibroblasts

Ji Woong Jung, Il Ho Park, Jung Sun Cho, Heung Man Lee

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Naringenin, a natural predominant flavanone derived from plant food, has antifibrotic activity. The purposes of this study were to determine the effect of naringenin on myofibroblast differentiation and extracellular matrix (ECM) production in nasal polyp-derived fibroblasts (NPDFs) and to determine the molecular mechanism of the effect of naringenin on NPDFs. NPDFs were incubated and treated with transforming growth factor (TGF)-β1. The expression of alpha smooth muscle actin (α-SMA), fibronectin, and collagen type I mRNA was determined by a reverse transcription-polymerase chain reaction, and the expression of those proteins was determined by immunofluorescence staining or Western blotting. Expression of several signaling molecules of the TGF-β1 pathway was evaluated by Western blot analysis. Naringenin inhibits expression of an indicator of myofibroblast differentiation (α-SMA) and ECM production, including collagen type 1 and fibronectin. Naringenin only suppressed the expression of extracellular signal-regulated protein kinase (pERK)1/2 among evaluated signaling molecules. PD98059 (a specific inhibitor of ERK1/2 kinase) also suppressed the increased expression of fibronectin, collagen type I, and α-SMA in TGF-β1-induced NPDFs. These results suggest the possibility that naringenin may play an inhibitory role in the production of the ECM in the development of nasal polyps.

Original languageEnglish
Pages (from-to)463-467
Number of pages5
JournalPhytotherapy Research
Volume27
Issue number3
DOIs
Publication statusPublished - 2013 Mar 1

Fingerprint

Nasal Polyps
Extracellular Signal-Regulated MAP Kinases
Extracellular Matrix
Fibroblasts
Transforming Growth Factors
Collagen Type I
Fibronectins
Myofibroblasts
Western Blotting
Edible Plants
Mitogen-Activated Protein Kinase 3
Protein Kinases
Reverse Transcription
Fluorescent Antibody Technique
Smooth Muscle
naringenin
Actins
Staining and Labeling
Polymerase Chain Reaction
Messenger RNA

Keywords

  • alpha smooth muscle actin
  • extracellular matrix
  • mitogen-activated protein kinases
  • myofibroblast
  • nasal polyp
  • transforming growth factor-beta 1

ASJC Scopus subject areas

  • Pharmacology

Cite this

Naringenin inhibits extracellular matrix production via extracellular signal-regulated kinase pathways in nasal polyp-derived fibroblasts. / Jung, Ji Woong; Park, Il Ho; Cho, Jung Sun; Lee, Heung Man.

In: Phytotherapy Research, Vol. 27, No. 3, 01.03.2013, p. 463-467.

Research output: Contribution to journalArticle

@article{7452e11fb23d44b2acf2795eabe294e4,
title = "Naringenin inhibits extracellular matrix production via extracellular signal-regulated kinase pathways in nasal polyp-derived fibroblasts",
abstract = "Naringenin, a natural predominant flavanone derived from plant food, has antifibrotic activity. The purposes of this study were to determine the effect of naringenin on myofibroblast differentiation and extracellular matrix (ECM) production in nasal polyp-derived fibroblasts (NPDFs) and to determine the molecular mechanism of the effect of naringenin on NPDFs. NPDFs were incubated and treated with transforming growth factor (TGF)-β1. The expression of alpha smooth muscle actin (α-SMA), fibronectin, and collagen type I mRNA was determined by a reverse transcription-polymerase chain reaction, and the expression of those proteins was determined by immunofluorescence staining or Western blotting. Expression of several signaling molecules of the TGF-β1 pathway was evaluated by Western blot analysis. Naringenin inhibits expression of an indicator of myofibroblast differentiation (α-SMA) and ECM production, including collagen type 1 and fibronectin. Naringenin only suppressed the expression of extracellular signal-regulated protein kinase (pERK)1/2 among evaluated signaling molecules. PD98059 (a specific inhibitor of ERK1/2 kinase) also suppressed the increased expression of fibronectin, collagen type I, and α-SMA in TGF-β1-induced NPDFs. These results suggest the possibility that naringenin may play an inhibitory role in the production of the ECM in the development of nasal polyps.",
keywords = "alpha smooth muscle actin, extracellular matrix, mitogen-activated protein kinases, myofibroblast, nasal polyp, transforming growth factor-beta 1",
author = "Jung, {Ji Woong} and Park, {Il Ho} and Cho, {Jung Sun} and Lee, {Heung Man}",
year = "2013",
month = "3",
day = "1",
doi = "10.1002/ptr.4735",
language = "English",
volume = "27",
pages = "463--467",
journal = "Phytotherapy Research",
issn = "0951-418X",
publisher = "John Wiley and Sons Ltd",
number = "3",

}

TY - JOUR

T1 - Naringenin inhibits extracellular matrix production via extracellular signal-regulated kinase pathways in nasal polyp-derived fibroblasts

AU - Jung, Ji Woong

AU - Park, Il Ho

AU - Cho, Jung Sun

AU - Lee, Heung Man

PY - 2013/3/1

Y1 - 2013/3/1

N2 - Naringenin, a natural predominant flavanone derived from plant food, has antifibrotic activity. The purposes of this study were to determine the effect of naringenin on myofibroblast differentiation and extracellular matrix (ECM) production in nasal polyp-derived fibroblasts (NPDFs) and to determine the molecular mechanism of the effect of naringenin on NPDFs. NPDFs were incubated and treated with transforming growth factor (TGF)-β1. The expression of alpha smooth muscle actin (α-SMA), fibronectin, and collagen type I mRNA was determined by a reverse transcription-polymerase chain reaction, and the expression of those proteins was determined by immunofluorescence staining or Western blotting. Expression of several signaling molecules of the TGF-β1 pathway was evaluated by Western blot analysis. Naringenin inhibits expression of an indicator of myofibroblast differentiation (α-SMA) and ECM production, including collagen type 1 and fibronectin. Naringenin only suppressed the expression of extracellular signal-regulated protein kinase (pERK)1/2 among evaluated signaling molecules. PD98059 (a specific inhibitor of ERK1/2 kinase) also suppressed the increased expression of fibronectin, collagen type I, and α-SMA in TGF-β1-induced NPDFs. These results suggest the possibility that naringenin may play an inhibitory role in the production of the ECM in the development of nasal polyps.

AB - Naringenin, a natural predominant flavanone derived from plant food, has antifibrotic activity. The purposes of this study were to determine the effect of naringenin on myofibroblast differentiation and extracellular matrix (ECM) production in nasal polyp-derived fibroblasts (NPDFs) and to determine the molecular mechanism of the effect of naringenin on NPDFs. NPDFs were incubated and treated with transforming growth factor (TGF)-β1. The expression of alpha smooth muscle actin (α-SMA), fibronectin, and collagen type I mRNA was determined by a reverse transcription-polymerase chain reaction, and the expression of those proteins was determined by immunofluorescence staining or Western blotting. Expression of several signaling molecules of the TGF-β1 pathway was evaluated by Western blot analysis. Naringenin inhibits expression of an indicator of myofibroblast differentiation (α-SMA) and ECM production, including collagen type 1 and fibronectin. Naringenin only suppressed the expression of extracellular signal-regulated protein kinase (pERK)1/2 among evaluated signaling molecules. PD98059 (a specific inhibitor of ERK1/2 kinase) also suppressed the increased expression of fibronectin, collagen type I, and α-SMA in TGF-β1-induced NPDFs. These results suggest the possibility that naringenin may play an inhibitory role in the production of the ECM in the development of nasal polyps.

KW - alpha smooth muscle actin

KW - extracellular matrix

KW - mitogen-activated protein kinases

KW - myofibroblast

KW - nasal polyp

KW - transforming growth factor-beta 1

UR - http://www.scopus.com/inward/record.url?scp=84874932659&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874932659&partnerID=8YFLogxK

U2 - 10.1002/ptr.4735

DO - 10.1002/ptr.4735

M3 - Article

C2 - 22674629

AN - SCOPUS:84874932659

VL - 27

SP - 463

EP - 467

JO - Phytotherapy Research

JF - Phytotherapy Research

SN - 0951-418X

IS - 3

ER -